Literature DB >> 9204091

Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials.

W J Cunliffe1, R Caputo, B Dreno, L Förström, M Heenen, C E Orfanos, Y Privat, A Robledo Aguilar, J Meynadier, M Alirezai, S Jablonska, A Shalita, J S Weiss, D K Chalker, C N Ellis, A Greenspan, H I Katz, I Kantor, L E Millikan, J M Swinehart, L Swinyer, C Whitmore, J Czernielewski, M Verschoore.   

Abstract

BACKGROUND: Adapalene is a new chemical entity that exhibits tretinoin-like activities in the terminal differentiation process.
OBJECTIVE: We evaluated a dose range effect of two concentrations of adapalene gel as acne treatment and compared adapalene 0.1% gel with tretinoin 0.025% gel in the treatment of acne patients in two large multicenter studies.
METHODS: Multicenter, investigator-masked, parallel group studies including 89 acne patients in the dose range study and 591 patients in the concurrent controlled studies were conducted.
RESULTS: Adapalene gel 0.1% was significantly more effective in treating acne lesions than 0.03% adapalene gel. Adapalene gel 0.1% was significantly more effective than 0.025% or tretinoin gel in one study and of the same effectiveness in the other study. Adapalene gel was always better tolerated than tretinoin gel.
CONCLUSION: Adapalene 0.1% gel is a safe and effective treatment of acne vulgaris.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9204091     DOI: 10.1016/s0190-9622(97)70056-2

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  Adapalene 0.3% for the treatment of acne in women.

Authors:  Diane Berson; Andrew Alexis
Journal:  J Clin Aesthet Dermatol       Date:  2013-10

2.  Tretinoin Nanogel 0.025% Versus Conventional Gel 0.025% in Patients with Acne Vulgaris: A Randomized, Active Controlled, Multicentre, Parallel Group, Phase IV Clinical Trial.

Authors:  B S Chandrashekhar; M Anitha; Mukesh Ruparelia; Pradyumna Vaidya; Riyaz Aamir; Sunil Shah; S Thilak; Sanjeev Aurangabadkar; Sandeep Pal; Abir Saraswat; Jayesh J Sanmukhani
Journal:  J Clin Diagn Res       Date:  2015-01-01

Review 3.  Transdermal penetration of topical drugs used in the treatment of acne.

Authors:  Andrea Krautheim; Harald Gollnick
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 4.  Adapalene: a review of its use in the treatment of acne vulgaris.

Authors:  John Waugh; Stuart Noble; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Optimization and validation of high-performance chromatographic condition for simultaneous determination of adapalene and benzoyl peroxide by response surface methodology.

Authors:  Yi-Cheng Chen; Pi-Ju Tsai; Yaw-Bin Huang; Pao-Chu Wu
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

6.  Fixed-Combination Gels of Adapalene and Benzoyl Peroxide Provide Optimal Percutaneous Absorption Compared to Monad Formulations of These Compounds: Results from Two In Vitro Studies.

Authors:  Hanan Osman-Ponchet; Karine Sevin; Alexandre Gaborit; Nathalie Wagner; Michel Poncet
Journal:  Dermatol Ther (Heidelb)       Date:  2016-11-30

Review 7.  A review of diagnosis and treatment of acne in adult female patients.

Authors:  A U Tan; B J Schlosser; A S Paller
Journal:  Int J Womens Dermatol       Date:  2017-12-23

8.  A review of the use of adapalene for the treatment of acne vulgaris.

Authors:  Suleyman Piskin; Erol Uzunali
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

9.  Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study.

Authors:  Linda Stein Gold; Jonathan Weiss; Maria Jose Rueda; Hong Liu; Emil Tanghetti
Journal:  Am J Clin Dermatol       Date:  2016-06       Impact factor: 7.403

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.